Sensorion reports full-year 2024 results, provides corporate update and announces availability of full-year report

Montpellier, france--(business wire)--regulatory news: sensorion (fr0012596468 – alsen) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2024 results, provided a corporate update, and announced the availability of the full-year report. “this past year has been an exceptional period of progress on clinical and corporate development fronts,” commented nawal ouzren.
CIO Ratings Summary
CIO Quant Ranking